DiaMedica Therapeutics Inc. Stock

$4.60

1.32% yesterday

Nasdaq, Jul 22, 10:04 pm CET

ISIN

CA25253X2077

Symbol

DMAC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

DiaMedica Therapeutics Inc. Stock price

$4.60

-1.90 29.23% 5Y

Nasdaq, Closing price Tue, Jul 22 2025

+0.06 1.32%

ISIN

CA25253X2077

Symbol

DMAC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$194.7m

Enterprise Value

$158.4m

Net debt

positive

Cash

$36.3m

Shares outstanding

42.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

5.7

Financial Health

Equity Ratio

87.9%

Return on Equity

-60.0%

ROCE

-85.1%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-29.0m | $-40.6m

EBIT

$-29.1m | $-35.6m

Net Income

$-27.0m | $-34.0m

Free Cash Flow

$-22.6m

EPS

$-0.6

FCF per Share

$-0.5

Short interest

4.6%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

DiaMedica Therapeutics Inc. Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a DiaMedica Therapeutics Inc. forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a DiaMedica Therapeutics Inc. forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from DiaMedica Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	8.05 8.05	3% 3% -
- Research and Development Expense	21 21	60% 60% -
EBITDA	-29 -29	35% 35% -
- Depreciation and Amortization	0.04 0.04	33% 33% -
EBIT (Operating Income) EBIT	-29 -29	35% 35% -
Net Profit	-27 -27	40% 40% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

DiaMedica Therapeutics Inc. Stock News

Neutral

Business Wire

●

one day ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction....

Neutral

Business Wire

●

6 days ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of DM199. DM199, rin...

Neutral

Business Wire

●

29 days ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses th...

More DiaMedica Therapeutics Inc. News

Company Profile

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Head office	Canada
CEO	Rick Pauls
Employees	28
Founded	2000
Website	www.diamedica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now